The company for the energy age of health.

A general-wellness company built on one idea — that vitality is a function of energy, and energy can be measured, corrected and protected.

What E4L is

Modern medicine is built on chemistry. E4L is built on the layer beneath it — energy and information. Our organizing idea is the Vitality Equation: Vitality = Information × Voltage ÷ Resistance. Raise the quality of a body's information, restore its cellular voltage, lower the resistance that drains it, and vitality follows. This is not a rejection of medicine; it is the layer that acts before symptoms, framed under the Beyond Medicine banner — additive, never anti-medicine.

Around that idea sits a full ecosystem — a consumer platform and a practitioner channel — feeding a single AI diagnostic engine, FIELD (Functional, Integrative, Energetic, Longevity Diagnostics). The devices, the infoceuticals, the app and the film audience all generate the signal that FIELD learns from. E4L is the ecosystem for FIELD. The Company owns FIELD outright — it came in with the NES Health LLC subsidiary in the acquisition — and owns its products outright, with no licence caveat.

A new company, launching with acquired assets — and revenue from day one.

E4L, Inc. is a new company — a Nevada corporation formed in 2026, operating from Salt Lake City, Utah — that acquired the assets of a business built in the United Kingdom over the prior two decades, including a 26-year, 1M+-scan bioenergetic dataset. It acquired the products, intellectual property, customer base and 26-year data asset of the former XPO Health / NES Health group — specifically the operating subsidiaries that own the miHealth device and FIELD platform (NES Health LLC), the GEM wearable (Energy 4 Life LLC), the Infoceutical product line, and the BWS practitioner system. With the practitioner base comes revenue from day one: ~650 acquired practitioners whose infoceutical wholesale orders were running at ≈$3.5M a year at close (2026) — the same figure the forecast starts from. The growth products — the GEM wearable, the consumer app, the new miHealth and FIELD — are brand new, with zero revenue history, and the forecast presents them as stated assumptions, not track record. The full mechanics of the acquisition and the solvent wind-down of the UK entity are set out in the Disclosure Memorandum provided to every investor.

Important framing. E4L, Inc. is a new company. The legacy group's historical revenue is not presented as E4L's own track record — it informs the assumptions behind the forecast only. What was acquired are assets, technology, a customer base and data; what is being built is new.

Products & six revenue lines

The portfolio relaunches subscription-first, spanning two engines:

Consumer

GEM app — free 30-day trial → Member ($10/mo) → GEM plan ($30/mo, requires GEM) → Guided ($90/mo, three Infoceuticals shipped monthly, three-month commitment).
GEM wearable — a $397 wrist-worn device delivering hourly energetic corrections.
Infoceuticals — "energized structured water" supplements; Cell Driver+ from $38, $33 a bottle for the rest (three for $99) or Guided at $90/mo; a re-scan every 30 days refreshes the three and drives recurring reorders.

Practitioner (B2B2C)

miHealth device — $5,000 bioenergetic device, practitioner-led.
BWS / FIELD platform — the practitioner AI system on a rent-to-own recurring licence.
Wholesale consumables — recurring infoceutical wholesale to the active practitioner base.

These six lines map directly to the forecast segments: consumer subscriptions, consumer hardware, consumer consumables, practitioner devices, practitioner SaaS, and practitioner wholesale.

The numbers

Built bottoms-up from confirmed unit economics (forecast model v2.6, July 2026), revenue begins September 2026. The first revenue period is the Q4 2026 partial year (September–December) — the first quarter of revenue, not a full year — after which FY2027 is the first full year at $16.0M.

$2.7M

Q4 2026 revenue (partial year, first quarter of revenue)

$134.7M

FY2031 revenue

Q2 2027

First EBITDA-positive quarter

~82%

Blended gross margin

Annual summary ($000) — model v2.6 (FY26 = Q4 2026 partial year, Sep–Dec; first quarter of revenue)
Line	FY26	FY27	FY28	FY29	FY30	FY31
Total revenue	2,715	16,042	34,264	57,937	93,960	134,726
Gross profit	2,231	13,249	28,284	47,486	76,535	109,579
EBITDA	(461)	1,679	7,675	14,948	25,910	39,122
Net income (after D&A and ~25% blended tax)	(575)	1,209	5,523	10,914	19,061	28,900
Cash at year end (after tax)	3,832	4,446	9,734	20,209	38,768	67,220

Forward-looking projections based on management assumptions; actual results will differ. Cash never turns negative in any modeled scenario (minimum ~$1.2M). Full detail — including the cash-flow statement and balance sheet (the company carries no debt) — is in the Forecast & Financial Statements document and the live model.

The raise

E4L is raising $5M on a YC-style SAFE with a $73,000,000 post-money valuation cap plus a 15% discount, converting at the lower of the two. The cap is a negotiated term of this round. The instrument converts into Class A Preferred at the next priced round — intended within ~18 months — and if a sale comes first, the same lower-of terms apply to the sale price. SAFEs carry no voting rights until conversion. Accredited investors only, mainly family offices, under Reg D Rule 506(c) — each investor's accredited status is verified, not merely self-certified. There is no escrow and no tranching.

Equity structure & founder alignment. A single 1× non-participating liquidation preference, for cash actually invested. New money — Class A Preferred on SAFE conversion — is senior; legacy cash sits in Class B Preferred, junior: Massey Developments' $3.2M (pegged to cost) and one early investor's ~$1.6M restricted. The founder's own upside sits in ordinary Founder Common — the same economics as every common holder — so nobody double-dips. Harry Massey has contributed roughly $15–20M of real invested capital over 20+ years — reinvested funding, $3.2M+ of loans, two decades of IP development, the customer base and the operating subsidiaries — context for his commitment, not the value of his holding company's stock; all contributed to E4L as equity, with no repayable note or royalty. His Founder Common carries ordinary common economics — one vote per share, no preference; his control comes from his majority ownership (83.21% post-SAFE at the cap) together with a board director-designation right that lets him designate all three board seats — not from any super-voting multiple.

Team & board

Leadership. Harry Massey (CEO & Founder) leads a Salt Lake City team: Susan Kichuk (Strategic Execution), Antony "Tony" Watson (CRO & President, Practitioner Channel), Jeremy Johnson (Supply Chain & Operations), Matt Olaya (Director of Marketing), and Piyush Hinduja (Head of Product).

Board of directors. Harry Massey (Chairman & CEO) and Susan Kichuk — a PhD business scientist who as CEO scaled The Targeted Strategies Group to over $11 billion of in-force policies, Canada's #1 permanent-life-insurance brokerage — with one board seat currently open.

Full bios are in the Team & Organization document. Advisors: Prof. Hemal Patel (UC San Diego) and Dr. Zulia Frost.

Confidential. For accredited investors only. Securities offered under Rule 506(c) of Regulation D; accredited status is verified before any subscription is accepted. E4L, Inc. is a general-wellness company; its products support energy, resilience and wellbeing and are not intended to diagnose, treat, cure or prevent any disease. This document contains illustrative projections based on management assumptions; actual results will differ. Company name to be conformed to the name on the Company’s filed Nevada charter.